March 2017

Leveraging Cognitive Measures in Clinical Trials

Webinars Back to resource centre 11 January 2023 Leveraging Cognitive Measures in Clinical Trials This webinar discussed the assessment of cognitive function throughout the development of drugs for both CNS and non-CNS indications. It included a discussion of methodological considerations for the design of clinical trials and approaches to the analysis and interpretation of cognitive outcome measures for the evaluation

Leveraging Cognitive Measures in Clinical Trials Read More »

Understanding the Clinical Assessment of Abuse Potential during CNS Drug Development

Webinars Back to resource centre 11 January 2023 Understanding the Clinical Assessment of Abuse Potential during CNS Drug Development This free webinar discussed the why, when and how of collecting, evaluating and interpreting abuse potential data throughout CNS drug development, including a discussion of the design, analysis and interpretation of human abuse potential studies.  Speaker: Kerri A. Schoedel, PhD, Director and

Understanding the Clinical Assessment of Abuse Potential during CNS Drug Development Read More »

Assessing Cognitive Safety of Drugs in Clinical Development

Webinars Back to resource centre 11 January 2023 Assessing Cognitive Safety of Drugs in Clinical Development In this webinar, Dr Kenton Zavitz, Director of Clinical Affairs discusses assessing cognitive safety of drugs in clinical development.  Speakers: Kenton H. Zavitz, PhD, Director of Clinical Affairs Pradeep Nathan, PhD, Vice President Neuroscience Scientific Strategy Lead and Head, Neuroscience Center of Innovation, inVentiv Health Key Discussion Points: What

Assessing Cognitive Safety of Drugs in Clinical Development Read More »

CANTAB assessments used in EBBINGHAUS cognitive function trial for Amgen’s evolocumab

News Back to resource centre 16 March 2017 CANTAB assessments used in EBBINGHAUS cognitive function trial for Amgen’s evolocumab Cambridge Cognition today reports its involvement in Amgen’s EBBINGHAUS study with full results being presented at the American College of Cardiology Annual Scientific Session on 18 March 2017.Cambridge Cognition reports its involvement in Amgen’s EBBINGHAUS study with full results being presented at the American College of Cardiology Annual Scientific Session on

CANTAB assessments used in EBBINGHAUS cognitive function trial for Amgen’s evolocumab Read More »

Scroll to Top